We are a group of basic and clinical investigators looking for unmet biomarkers and therapeutic solutions for orphan ultra-rare kidney diseases and renal cancer.
Main achievements:
- Projects from competitive concurrence (7).
- Non-competitive projects from Advocacy Patients groups (Asdent and Hipofam) (2).
- Original manuscripts as principal authors or co-authors (27).
- Oral communications at the 23 annual meeting of the European Society of Pediatric Nephrology (ESPN) (3).
- International forum lectures (4).
- National meetings and Patient Journey days lectures (5).
- International surveys (9).
- Clinical trials in rare diseases (8).
- Clinical guidelines as members or reviewers (2).
- Member of the “Grup promotor d’experts per a impulsar el Hub de Teràpies Avançades i Emergents de Catalunya”.
- Member of the ESCRIBO project: “Estrategia para la Implementación de Cribado y Biomarcadores en el Sistema Nacional de Salud (Spain)”.
- Members of the Pediatric Research Hub (VHUH).
eCORE
- Personalized Medicine, Innovative Diagnostics, Molecular Imaging & Digital Health
- Woman & Child Health & Rare Diseases
Team
Group Leader
Anna Meseguer Navarro
Principal Investigator (PI)
Gema Ariceta Iraola, Gerard Cantero Recasens, Cristina Martínez Martínez
Researchers
Mónica Durán Fernández, Alejandro Cruz Gual, Sara Chocron de Benzaquen, Gloria Mª Fraga Rodriguez, Mercedes López González, Hector Rios Duro
PhD Students
Julieta Torchia, Maud Injeyan, Andrea Casal Pardo, Arne Van Durne, Carla Castells Esteve, Aitana Zapico Alonso
Lab Technicians
Anna Gelpí López, Maria Clotet Di Iorio, Eva Esquinas De La Cueva, Consuelo Garcia Carmona, Ashley Desire Lino Rivera
Nursing and Technical Staff
José Ramon Jarrín Luengo
Publications
Arévalo J*, Campoy I, Durán M, Nemours S, Areny A, Vall-Palomar M, Martínez C, Cantero-Recasens G, A Meseguer A*. (*) Co-corresponding author.
STAT3 phosphorylation at serine 727 activates specific genetic programs and promotes clear cell renal cell carcinoma (ccRCC) aggressiveness.
Sci Rep. 2023 Nov 9;13(1):19552.
DOI: 10.1038/s41598-023-46628-5.
IF: 4.997
Rey-Serra C, Tituaña-Fajardo J, Lin T, Herrero J, Miguel V, Barbas C, Meseguer A, Ramos R, Chaix A, Panda S, Lamas S.
Reciprocal regulation between the molecular clock and kidney injury.
Life Science Alliance 2023. 2023 Jul 24;6(10):e202201886.
DOI: 10.26508/lsa.202201886
IF: 4.405
Burballa C, Durán M, Martinez C, Ariceta G, Cantero-Recasens G*, Meseguer A*. *Co-last authors.
Isolation and characterization of exosome-enriched urinary extracellular vesicles (uEVs) from Dent’s Disease type 1 Spanish patients.
Nefrologia (Engl Ed). 2023 Dec:43 Suppl 2:77-84.
DOI: 10.1016/j.nefroe.2024.01.016.
IF: 2.6
Morello W, Baskin E, Jankauskiene A, Yalcinkaya F, Zurowska A, Puccio G, Serafinelli J, La Manna A, Krzemień G, Pennesi M, La Scola C, Becherucci F, Brugnara M, Yuksel S, Mekahli D, Chimenz R, De Palma D, Zucchetta P, Vajauskas D, Drozdz D, Szczepanska M, Caliskan S, Lombet J, Minoli DG, Guarino S, Gulleroglu K, Ruzgiene D, Szmigielska A, Barbi E, Ozcakar ZB, Kranz A, Pasini A, Materassi M, De Rechter S, Ariceta G, Weber LT, Marzuillo P, Alberici I, Taranta-Janusz K, Caldas Afonso A, Tkaczyk M, Català M, Cabrera Sevilla JE, Mehls O, Schaefer F, Montini G; PREDICT Study Group.
Antibiotic Prophylaxis in Infants with Grade III, IV, or V Vesicoureteral Reflux.
N Engl J Med. 2023 Sep 14;389(11):987-997.
DOI: 10.1056/NEJMoa2300161
IF: 158.5
Burballa C, Cantero-Recasens G, Prikhodina L, Ariceta G and Dent Study Group (Duran M, Meseguer A)
Clinical and genetic characteristics of Dent’s Disease type 1 in Europe
Nephrol Dial Transplant. 2023 May 31;38(6):1497-1507
DOI: 10.1093/ndt/gfac310.
IF: 6.1
Projects
Fucosylation in Clear Cell Renal Cell Carcinoma. STATing novel biomarkers and therapeutic strategies
Principal Investigator: Gerard Cantero Recasens
Agency: Asociación Española contra el cáncer (AECC Personal Investigador). INVES234762CANT
Funding: 150,000 €
Period: 2023-2026
La variabilidad fenotípica en pacientes afectados de Hipomagnesemia Familiar con Hipercalciuria y Nefrocalcinosis (HFHNC) como oportunidad para entender las bases fisiopatológicas de la enfermedad y para la búsqueda de soluciones terapéuticas.
Principal Investigator: Anna Meseguer
Agency: Fundación Senefro (Sociedad Española de Nefrologia) 2023
Funding: 24,000 €
Period: 2023-2024
Unravelling ClC-5 role on glycosylation and its link with proximal tubule functioning
Principal Investigator: Gerard Cantero Recasens
Agency: Mizutani Foundation for Glycoscience (Japan). REF230040
Funding: 41,509.78 €
Period: 2023-2024
Role of ClC-5 in renal fibrosis. Identification of potential biomarkers and therapeutic targets for the progression of Dent’s disease 1.
Principal Investigator: PI: Gerard Cantero Recasens. CO-PI: Anna Meseguer Navarro
Agency: Carlos III Health Institute. Ministry of Science and innovation (PI22/00741)
Funding: 123,420 €
Period: 2023-2025
Biomarkers, targets and therapeutic solutions to improve the care of patients affected by Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis (FHHNC).
Principal Investigator: Gema Ariceta
Agency: Carlos III Health Institute. Ministry of Science and innovation (PI22/01946).
Funding: 202,070 €
Period: 2023-25
Patents
Patent licensed to Ninevah Therapeutics
Priority Number: EP22382421.0
Priority Date: 14/09/2023
Applicants: Anna Meseguer Navarro (VHIR), Jazmine Paola Arévalo Bautista (VHIR), Miguel Chillón Rodríguez (ICREA, UAB, VHIR), Gonzalo Fernández-Miranda Pérez (Ninevah), Marc Ramis Castelltort (Ninevah)
Nucleic acid constructs and vectors for podocyte specific expression.
Priority Number: EP22382421.0
Priority Date: 02/05/2022
Applicants: 60% VHIR (UAB and ICREA), 40% Ninevah . OWNER ENTITY: Vall d'Hebrón University Hospital Foundation - Research Institute.
